KargesB, TittelSR, BeyA, et al.Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-based study. Lancet Diabetes Endocrinol, 2023; 11: 314–323.
2.
JohnsonSR, Holmes-WalkerDJ, CheeM, EarnestA, JonesTW.Universal subsidized continuous glucose monitoring funding for young people with type 1 diabetes: uptake and outcomes over 2 years, a population-based study. Diabetes Care, 2022; 45: 391–397.
3.
TauschmannM, HermannJM, FreibergC, et al.Reduction in diabetic ketoacidosis and severe hypoglycemia in pediatric type 1 diabetes during the first year of continuous glucose monitoring: a multicenter analysis of 3,553 subjects from the DPV registry. Diabetes Care, 2020; 43: E40–E42.
4.
AbrahamMB, KargesB, DovcK, et al.Clinical practice consensus guidelines 2022: assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes, 2022; 23: 1322–1340.
5.
GlaserN, FritschM, PriyambadaL, RewersA, CherubiniV, EstradaS, et al.ISPAD clinical practice consensus guidelines 2022: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes, 2022; 23: 835–856.
6.
GhettiS, KuppermannN, RewersA, et al.Cognitive function following diabetic ketoacidosis in children with new-onset or previously diagnosed type 1 diabetes. Diabetes Care, 2020; 43: 2768–2775.
7.
AyeT, MazaikaPK, MaurasN, et al.Impact of early diabetic ketoacidosis on the developing brain. Diabetes Care, 2019; 42: 443–449.
8.
BattelinoT, DanneT, BergenstalRM, et al.Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care, 2019; 42: 1593–1603.
9.
SteckAK, DongF, RasmussenCG, et al.CGM metrics predict imminent progression to type 1 diabetes: Autoimmunity Screening for Kids (ASK) study. Diabetes Care, 2022; 45: 365–371.
10.
DovcK, BodeBW, BattelinoT.Continuous and intermittent glucose monitoring in 2022. Diabetes Technol Ther, 2023; 25: S15–S29.
11.
Smigoc SchweigerD.Recent advances in immune-based therapies for type 1 diabetes. Horm Res Paediatr. Published online May 9, 2022.
12.
SimsEK, BesserREJ, DayanC, et al.Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes, 2022; 71: 610–623.
13.
SteckAK, DongF, TakiI, et al.Continuous glucose monitoring predicts progression to diabetes in autoantibody positive children. J Clin Endocrinol Metab, 2019; 104: 3337–3344.
14.
KarlFM, WinklerC, ZieglerAG, LaxyM, AchenbachP.Costs of public health screening of children for presymptomatic type 1 diabetes in Bavaria, Germany. Diabetes Care, 2022; 45: 837–844.
15.
HeroldKC, BundyBN, LongSA, et al.An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med, 2019; 381: 603–613.
16.
ElsayedNA, AleppoG, ArodaVR, et al.6. Glycemic targets: standards of care in diabetes—2023. Diabetes Care, 2023; 46: S97–S110.
17.
BolinderJ, AntunaR, Geelhoed-DuijvestijnP, et al.Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet, 2016; 388: 2254–2263.
18.
BoucherSE, GrayAR, WiltshireEJ, et al.Effect of 6 months of flash glucose monitoring in youth with type 1 diabetes and high-risk glycemic control: a randomized controlled trial. Diabetes Care, 2020; 43: 2388–2395.
19.
CharleerS, De BlockC, Van HuffelL, et al.Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care, 2020; 43: 389–397.
20.
BeckRW, RiddlesworthT, RuedyK, et al.Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The Diamond Randomized Clinical Trial. JAMA, 2017; 317: 371–378.
21.
LindM, ÓlafsdóttirAF, HirschIB, et al.Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER study) by CGM in people with type 1 diabetes treated with MDI. Diabetes Care, 2021; 44: 141–149.
22.
VisserMM, CharleerS, FieuwsS, et al.Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet, 2021; 397: 2275–2283.
23.
PaulSK, KleinK, ThorstedBL, WoldenML, KhuntiK.Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol, 2015; 14: 100.
24.
BayfieldNGR, BiboL, BudgeonC, LarbalestierR, BriffaT.Conventional glycaemic control may not be beneficial in diabetic patients following cardiac surgery. Heart Lung Circ, 2022; 31: 1692–1698.
25.
LaffelLM, KanapkaLG, BeckRW, et al.Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA, 2020; 323: 2388–2396.
26.
Cardona-HernandezR, SchwandtA, AlkandariH, et al.Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the International Pediatric Registry SWEET. Diabetes Care, 2021; 44: 1176–1184.
27.
HáskováA, RadovnickáL, PetruželkováL, et al.Real-time CGM is superior to flash glucose monitoring for glucose control in type 1 diabetes: the CORRIDA randomized controlled trial. Diabetes Care, 2020; 43: 2744–2750.
28.
GuerciB, RousselR, Levrat-GuillenF, et al.Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre System initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol Ther, 2023; 2: 20–30.
29.
Eeg-OlofssonK, SvenssonAM, FranzénS, Ahmed IsmailH, TörnblomM, Levrat-GuillenF.Real-world study of flash glucose monitoring among adults with type 2 diabetes within the Swedish National Diabetes Register. Diabetes Vasc Dis Res, 2023; 20: 14791641211067418.
30.
BeckRW, BergenstalRM, RiddlesworthTD, et al.Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019; 42: 400–405.
31.
BeckRW.The association of time in range and diabetic complications: the evidence is strong. Diabetes Technol Ther, 2023; 25: 375–377.
32.
MarsoSP, McGuireDK, ZinmanB, et al.Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med, 2017; 377: 723–732.
33.
BergenstalRM, Hachmann-NielsenE, KvistK, PetersAL, TarpJM, BuseJB.Increased derived time in range is associated with reduced risk of major adverse cardiovascular events, severe hypoglycemia, and microvascular events in type 2 diabetes: a post hoc analysis of DEVOTE. Diabetes Technol Ther, 2023; 25: 378–383.
34.
BattelinoT, DanneT, EdelmanSV.et al. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/mL versus insulin degludec 100 units/mL in type 1 diabetes: the head-to-head randomized controlled InRange trial. Diabetes Obes Metab, 2023; 25: 545–555.
35.
BattelinoT, AlexanderCM, AmielSA, et al.Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol, 2023; 11: 42–57.
36.
AddalaA, AuzanneauM, MillerK, et al.A decade of disparities in diabetes technology use and HBA1c in pediatric type 1 diabetes: a transatlantic comparison. Diabetes Care, 2021; 44: 133–140.
37.
AddalaA, DingV, ZaharievaDP, et al.Disparities in hemoglobin A1cLevels in the first year after diagnosis among youths with type 1 diabetes offered continuous glucose monitoring. JAMA Netw Open, 2023; 6: e238881
38.
NiK, TampeCA, SolK, RichardsonDB, PereiraRI.Effect of CGM access expansion on uptake among patients on Medicaid with diabetes. Diabetes Care, 2023; 46: 391–398.
39.
RotondiMA, WongO, RiddellM, PerkinsB.Population-level impact and cost-effectiveness of continuous glucose monitoring and intermittently scanned continuous glucose monitoring technologies for adults with type 1 diabetes in Canada: a modeling study. Diabetes Care, 2022; 45: 2012–2019.
40.
TauschmannM, ForlenzaG, HoodK, et al.Clinical practice consensus guidelines 2022: diabetes technologies: glucose monitoring. Pediatr Diabetes, 2022; 23: 1390–1405.
41.
SherrJL, SchoelwerM, Dos SantosTJ, et al.ISPAD clinical practice consensus guidelines 2022: diabetes technologies: insulin delivery. Pediatr Diabetes, 2022; 23: 1406–1431.
42.
ElSayedNA, AleppoG, ArodaVR, et al.7. Diabetes technology: standards of care in diabetes — 2023. Diabetes Care, 2023; 46 (Suppl 1): S111–S127.
43.
RiddellMC, GallenIW, SmartCE, et al.Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol, 2017; 5: 377–390.
44.
AdolfssonP, TaplinCE, ZaharievaDP, et al.ISPAD clinical practice consensus guidelines 2022: exercise in children and adolescents with diabetes. Pediatr Diabetes, 2022; 23: 1341–1372.
45.
RiddellMC, LiZ, GalRL, et al.Examining the acute glycemic effects of different types of structured exercise sessions in type 1 diabetes in a real-world setting: the Type 1 Diabetes and Exercise Initiative (T1DEXI). Diabetes Care, 2023; 46: 704–713.
46.
RiddellMC, LiZ, BeckRW, et al.More time in glucose range during exercise days than sedentary days in adults living with type 1 diabetes. Diabetes Technol Ther, 2021; 23: 376–383.
47.
Van WeenenE, BanholzerN, FöllS, et al.Glycaemic patterns of male professional athletes with type 1 diabetes during exercise, recovery and sleep: retrospective, observational study over an entire competitive season. Diabetes, Obes Metab, 2023; 25: 2616–2625.
48.
AvariP, LumbA, FlanaganD, et al.Continuous glucose monitoring within hospital: a scoping review and summary of guidelines from the Joint British Diabetes Societies for Inpatient Care. J Diabetes Sci Technol, 2023; 17: 611–624.
49.
SpanakisEK, UrrutiaA, GalindoRJ, et al.Continuous glucose monitoring–guided insulin administration in hospitalized patients with diabetes: a randomized clinical trial. Diabetes Care, 2022; 45: 2369–2375.
50.
SpanakisEK, CookCB, KulasaK, et al.A consensus statement for continuous glucose monitoring metrics for inpatient clinical trials. J Diabetes Sci Technol. Published online August 17, 2023. doi: 10.1177/19322968231191104.
51.
OserTK, HallTL, DickinsonLM, et al.Continuous glucose monitoring in primary care: understanding and supporting clinicians’ use to enhance diabetes care. Ann Fam Med, 2022; 20: 541–547.
52.
PembertonJS, WilmotEG, Barnard-KellyK, et al.CGM accuracy: contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): a narrative review. Diabetes Obes Metab, 2023; 25: 916–939.
